Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Acceleron shares not pricing in PAH opportunity, says Piper Sandler » 05:05
05/26/20
05/26
05:05
05/26/20
05:05
XLRN

Acceleron

$98.64 /

-0.43 (-0.43%)

While Acceleron Pharma…

While Acceleron Pharma shares are up 85% year-to-date even before the PULSAR data have been detailed, sotatercept's opportunity in pulmonary arterial hypertension is not fully baked into the stock, Piper Sandler analyst Christopher Raymond tells investors in a research note after taking over coverage of the name. While management has "provided a decent floor in terms of expectations for the data, we like the chances for upside," says the analyst. He keeps an Overweight rating on the shares with a $135 price target.

ShowHide Related Items >><<
XLRN Acceleron
$98.64 /

-0.43 (-0.43%)

XLRN Acceleron
$98.64 /

-0.43 (-0.43%)

05/12/20 SVB Leerink
Acceleron price target raised to $127 from $104 at SVB Leerink
05/08/20 Credit Suisse
Acceleron price target raised to $123 from $99 at Credit Suisse
04/16/20 Citi
Citi opens 'positive 90-day catalyst watch' on Acceleron
04/06/20 Piper Sandler
Acceleron still top pick after Rebloyzl indication approval, says Piper Sandler
XLRN Acceleron
$98.64 /

-0.43 (-0.43%)

XLRN Acceleron
$98.64 /

-0.43 (-0.43%)

Over a week ago
Conference/Events
Acceleron management to meet virtually with Oppenheimer » 08:13
05/14/20
05/14
08:13
05/14/20
08:13
XLRN

Acceleron

$99.69 /

-1.02 (-1.01%)

Virtual Meeting with…

Virtual Meeting with management to be held on May 14 hosted by Oppenheimer.

ShowHide Related Items >><<
XLRN Acceleron
$99.69 /

-1.02 (-1.01%)

XLRN Acceleron
$99.69 /

-1.02 (-1.01%)

05/12/20 SVB Leerink
Acceleron price target raised to $127 from $104 at SVB Leerink
05/08/20 Credit Suisse
Acceleron price target raised to $123 from $99 at Credit Suisse
04/16/20 Citi
Citi opens 'positive 90-day catalyst watch' on Acceleron
04/06/20 Piper Sandler
Acceleron still top pick after Rebloyzl indication approval, says Piper Sandler
XLRN Acceleron
$99.69 /

-1.02 (-1.01%)

XLRN Acceleron
$99.69 /

-1.02 (-1.01%)

Hot Stocks
Acceleron announces pulication of sotatercept data in STM journal » 16:04
05/13/20
05/13
16:04
05/13/20
16:04
XLRN

Acceleron

$100.80 /

+0.09 (+0.09%)

Acceleron Pharma…

Acceleron Pharma announced that research published in the journal Science Translational Medicine describes how a murine version of the investigational agent sotatercept acts to restore balance in key signaling pathways whose disruption drives the disease pathology of pulmonary arterial hypertension. The research may provide a mechanistic rationale for the positive topline results reported earlier this year from the PULSAR Phase 2 clinical trial of sotatercept in patients with PAH. The article reports that in experimental human cell-based tissue and animal models of pulmonary hypertension and PAH, sotatercept exhibited consistent effects across multiple components of disease, including suppressed proliferation of pulmonary arterial smooth muscle and microvascular endothelial cells, reduced pulmonary pressures, lessened right ventricular hypertrophy, improved right ventricular function, and attenuated vascular remodeling. The anti-remodeling effects were not seen with a PAH standard-of-care therapy included in the study as a comparator. The researchers concluded that sotatercept exerted its beneficial effects on these pathologic hallmarks by selectively binding the TGF-beta superfamily ligands activin A, activin B, and growth differentiation factor (GDF) 8 and GDF11. Signaling of these ligands, which may induce cellular proliferation, has been found to be upregulated in PAH-which in turn may impair signaling of bone morphogenetic protein receptor type 2 (BMPR-II), which is thought to be protective.

ShowHide Related Items >><<
XLRN Acceleron
$100.80 /

+0.09 (+0.09%)

XLRN Acceleron
$100.80 /

+0.09 (+0.09%)

05/12/20 SVB Leerink
Acceleron price target raised to $127 from $104 at SVB Leerink
05/08/20 Credit Suisse
Acceleron price target raised to $123 from $99 at Credit Suisse
04/16/20 Citi
Citi opens 'positive 90-day catalyst watch' on Acceleron
04/06/20 Piper Sandler
Acceleron still top pick after Rebloyzl indication approval, says Piper Sandler
XLRN Acceleron
$100.80 /

+0.09 (+0.09%)

XLRN Acceleron
$100.80 /

+0.09 (+0.09%)

Recommendations
Acceleron price target raised to $127 from $104 at SVB Leerink » 09:20
05/12/20
05/12
09:20
05/12/20
09:20
XLRN

Acceleron

$105.49 /

+3.17 (+3.10%)

SVB Leerink analyst…

SVB Leerink analyst Geoffrey Porges raised the firm's price target on Acceleron to $127 from $104 and keeps an Outperform rating on the shares. The analyst notes that Acceleron reported Q1 earnings and provided interim corporate updates following the first full quarter of Reblozyl sales and reported encouraging Q1 net Reblozyl sales of about $8M and royalties of $1.5M. Considering that this revenue was all attributed to the less significant beta thalassemia indication, and expectations were negligible, this is a creditable revenue result, he contends.

ShowHide Related Items >><<
XLRN Acceleron
$105.49 /

+3.17 (+3.10%)

XLRN Acceleron
$105.49 /

+3.17 (+3.10%)

05/08/20 Credit Suisse
Acceleron price target raised to $123 from $99 at Credit Suisse
04/16/20 Citi
Citi opens 'positive 90-day catalyst watch' on Acceleron
04/06/20 Piper Sandler
Acceleron still top pick after Rebloyzl indication approval, says Piper Sandler
04/06/20 Oppenheimer
Acceleron price target raised to $112 from $108 at Oppenheimer
XLRN Acceleron
$105.49 /

+3.17 (+3.10%)

XLRN Acceleron
$105.49 /

+3.17 (+3.10%)

Earnings
Acceleron reports Q1 EPS (95c), consensus (86c) » 16:08
05/11/20
05/11
16:08
05/11/20
16:08
XLRN

Acceleron

$104.91 /

+2.59 (+2.53%)

Reports Q1 revenue…

Reports Q1 revenue $4.34M, consensus $5.26M. "Acceleron is off to a strong start in 2020, propelled by one of the most eventful time periods in the Company's history," said Habib Dable, President and Chief Executive Officer of Acceleron. "The breadth and depth of our hematology program has been on full display, owing to the publication of the MEDALIST and BELIEVE Phase 3 luspatercept trial results in the prestigious New England Journal of Medicine and the recent FDA approval of REBLOZYL for the treatment of anemia in a population of patients with lower-risk MDS. We're thrilled that this first-in-class erythroid maturation agent, having received approvals in two distinct indications over a span of just five months, is now available in the U.S. to patients who have long needed a new option for treating their chronic anemias."

ShowHide Related Items >><<
XLRN Acceleron
$104.91 /

+2.59 (+2.53%)

05/08/20 Credit Suisse
Acceleron price target raised to $123 from $99 at Credit Suisse
04/16/20 Citi
Citi opens 'positive 90-day catalyst watch' on Acceleron
04/06/20 Piper Sandler
Acceleron still top pick after Rebloyzl indication approval, says Piper Sandler
04/06/20 Oppenheimer
Acceleron price target raised to $112 from $108 at Oppenheimer
Recommendations
Acceleron price target raised to $123 from $99 at Credit Suisse » 06:50
05/08/20
05/08
06:50
05/08/20
06:50
XLRN

Acceleron

$103.00 /

+2.01 (+1.99%)

Credit Suisse analyst…

Credit Suisse analyst Martin Auster raised the firm's price target on Acceleron to $123 from $99 and keeps an Outperform rating on the shares, saying that from the PULSAR top-line, he knows that sotatercept delivered statistical significant on a variety of meaningful endpoints, including PVR, 6mw, and WHO Functional Class changes. Auster is confident of that sotatercept can deliver deliver at least on the opportunity framed by the non-oral PAH market of $1B-$1.5B annual sales.

ShowHide Related Items >><<
XLRN Acceleron
$103.00 /

+2.01 (+1.99%)

04/16/20 Citi
Citi opens 'positive 90-day catalyst watch' on Acceleron
04/06/20 Piper Sandler
Acceleron still top pick after Rebloyzl indication approval, says Piper Sandler
04/06/20 Oppenheimer
Acceleron price target raised to $112 from $108 at Oppenheimer
04/06/20 H.C. Wainwright
Acceleron price target raised to $137 from $128 at H.C. Wainwright
Conference/Events
Acceleron participates in a virtual bus tour with Piper Sandler » 07:25
05/07/20
05/07
07:25
05/07/20
07:25
XLRN

Acceleron

$100.99 /

+1.57 (+1.58%)

Biotech Analyst Brill…

Biotech Analyst Brill holds a virtual bus tour with CEO Dable on May 7 at 7:30 am. Webcast Link

ShowHide Related Items >><<
XLRN Acceleron
$100.99 /

+1.57 (+1.58%)

04/16/20 Citi
Citi opens 'positive 90-day catalyst watch' on Acceleron
04/06/20 Piper Sandler
Acceleron still top pick after Rebloyzl indication approval, says Piper Sandler
04/06/20 Oppenheimer
Acceleron price target raised to $112 from $108 at Oppenheimer
04/06/20 H.C. Wainwright
Acceleron price target raised to $137 from $128 at H.C. Wainwright
Conference/Events
Acceleron participates in a virtual bus tour with Piper Sandler » 04:55
05/07/20
05/07
04:55
05/07/20
04:55
XLRN

Acceleron

$100.99 /

+1.57 (+1.58%)

Biotech Analyst Brill…

Biotech Analyst Brill holds a virtual bus tour with CEO Dable on May 7 at 7:30 am. Webcast Link

ShowHide Related Items >><<
XLRN Acceleron
$100.99 /

+1.57 (+1.58%)

04/16/20 Citi
Citi opens 'positive 90-day catalyst watch' on Acceleron
04/06/20 Piper Sandler
Acceleron still top pick after Rebloyzl indication approval, says Piper Sandler
04/06/20 Oppenheimer
Acceleron price target raised to $112 from $108 at Oppenheimer
04/06/20 H.C. Wainwright
Acceleron price target raised to $137 from $128 at H.C. Wainwright
Hot Stocks
Acceleron receives PRIME designation for sotatercept from EMA » 07:08
05/04/20
05/04
07:08
05/04/20
07:08
XLRN

Acceleron

$88.50 /

-1.98 (-2.19%)

Acceleron announced that…

Acceleron announced that the European Medicines Agency, or EMA, has granted Priority Medicines, or PRIME, designation to sotatercept for the treatment of patients with pulmonary arterial hypertension, or PAH. "Receiving PRIME designation for sotatercept from the EMA mere weeks after the FDA granted it Breakthrough Therapy designation further strengthens our belief that sotatercept could eventually alter the treatment landscape in PAH dramatically," said Habib Dable, President and CEO of Acceleron. "We're delighted that in their initial assessments of our clinical trial data, regulatory authorities in the US and Europe have put forth a path that could potentially help us expedite delivery of sotatercept to patients in need of new therapeutic options."

ShowHide Related Items >><<
XLRN Acceleron
$88.50 /

-1.98 (-2.19%)

04/16/20 Citi
Citi opens 'positive 90-day catalyst watch' on Acceleron
04/06/20 Piper Sandler
Acceleron still top pick after Rebloyzl indication approval, says Piper Sandler
04/06/20 Oppenheimer
Acceleron price target raised to $112 from $108 at Oppenheimer
04/06/20 H.C. Wainwright
Acceleron price target raised to $137 from $128 at H.C. Wainwright
Conference/Events
Acceleron participates in a virtual bus tour with Piper Sandler » 14:37
05/03/20
05/03
14:37
05/03/20
14:37
XLRN

Acceleron

$88.50 /

-1.98 (-2.19%)

Biotech Analyst Brill…

Biotech Analyst Brill holds a virtual bus tour with CEO Dable on May 7 at 7:30 am. Webcast Link

ShowHide Related Items >><<
XLRN Acceleron
$88.50 /

-1.98 (-2.19%)

04/16/20 Citi
Citi opens 'positive 90-day catalyst watch' on Acceleron
04/06/20 Piper Sandler
Acceleron still top pick after Rebloyzl indication approval, says Piper Sandler
04/06/20 Oppenheimer
Acceleron price target raised to $112 from $108 at Oppenheimer
04/06/20 H.C. Wainwright
Acceleron price target raised to $137 from $128 at H.C. Wainwright

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.